Immune drug trial offers new hope for women with early menopause to regain fertility
NCT ID NCT07509840
Summary
This study is testing whether a drug called rituximab, which calms the immune system, can help restore normal ovarian function and improve fertility in women with autoimmune premature ovarian failure (early menopause). The trial will enroll 40 women aged 18-38 who have this condition and wish to become pregnant. Participants will receive either rituximab or a placebo via infusion and will undergo ovarian stimulation, with some eligible for IVF treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE PREMATUR OVARIAN INSUFFIENCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Obstetrics and Gynecology, Karolinska University Hospital
RECRUITINGStockholm, 171 76, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Karolinska University Hospital
RECRUITINGStockholm, 17176, Sweden
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.